7.77
+1.44%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cabio Biotech Wuhan Co
Its shares trade on Shanghai under the ticker 688089.SS. It has been listed since 19 December 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥574.9m and net income of CN¥156.7m. At that date it held total assets of CN¥1.86bn and shareholders' equity of CN¥1.63bn.
CABIO Biotech (Wuhan) Co., Ltd. engages in the research, development, production, and sale of polyunsaturated fatty acids and nutrition products. The company is headquartered in Wuhan, Hubei. The company went IPO on 2019-12-19. The firm is mainly engaged in the research and development, production and sales of polyunsaturated fatty acids arachidonic acid (ARA), algal oil docosahexaenoic acid (DHA) and sialic acid (SA), and natural beta-carotene products. Its products are mainly used in infant formula food, dietary supplements, nutritional health food and formula food for special medical purposes. The firm integrates industrial strain-oriented optimization technology, fermentation fine control technology, and efficient separation, purification and preparation technology, and provides nutrient products and innovative solutions for customers in the global nutrition and health field through sustainable microbial synthesis and manufacturing methods. The firm mainly conducts its business in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 19 Dec 2019
- Employees
- 444
- Website
- cabio.cn ↗
Leadership
Pay as last reported
- Mr. Dewei YiChairman of the Board, General Manager, since 2015
- Mr. Bin DuVice Chairman of the Board, since 2015
- Mr. Huabiao WangChief Financial Officer, Director, since 2015
- Mr. Huarong YiDeputy General Manager, Secretary of the Board
- Mr. Anfeng GengDeputy General Manager
- Mr. Xiangyu LiDeputy General Manager
- Mr. Zhibo LiDeputy General Manager
- Ms. Xiaohe SuDirector
- Mr. Yifei WangDirector
- Ms. Chunyu ZhangDirector
- Mr. Xiangdong ChenIndependent Director
- Mr. Chun LiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cabio Biotech Wuhan produces ARA, DHA, and SA for infant formula and supplements.
- The company integrates industrial strain optimization and fermentation control technologies.
- Cabio Biotech employs 444 full-time staff in Wuhan, Hubei.
Weaknesses
- Cabio Biotech's products are limited to polyunsaturated fatty acids and nutrition segments.
- The firm relies on domestic and overseas markets for sales.
- Cabio Biotech's IPO date is 19 December 2019.
Opportunities
- Cabio Biotech can expand into global nutrition markets with sustainable microbial synthesis.
- The demand for natural beta-carotene in health food is growing.
- Cabio Biotech's technology supports innovative solutions for global health.
Threats
- Cabio Biotech faces competition in the Chinese Chemicals sector.
- The company's products are used in infant formula, which is highly regulated.
- Cabio Biotech's business is concentrated in the Materials sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.